Biomedicine_New Healthcare_Core Industries

Biomedicine

Dendreon US

Dendreon was founded in 1992 by Edgar Engleman, an immunologist from Stanford Medical School. It is a biomedical company committed to the R&D and applications of immunotherapies. Dendreon is actively exploring medicines for a variety of cancers. Its core product, Provenge, is the first and only FDA-approved cellular immunotherapy medicine for asymptomatic or minimally symptomatic metastatic castration-resistant prostate cancer (mCRPC).

Provenge is an autologous cellular immunotherapy medicine for treating prostate cancer. It treats asymptomatic metastatic castration-resistant prostate cancer (mCRPC) by re-programming the body's own immune cells to make them identify and attack advanced prostate cancer cells. The therapy is the first to systematically and clinically verify that the immune system can effectively suppress a tumour, launching a new era of cancer immunotherapy. After being launched in the US in 2010, it has been used by over 40,000 patients, which is a strong proof of its effect and reliability. As a first-line therapy for advanced prostate cancer recommended in the National Comprehensive Cancer Network (NCCN) guidelines, Provenge has been included in major health insurance schemes in the United States. Its production and quality management process is the industry's "golden standard", and its California factory is an FDA-designated cell plant training base.

In 2017, Sanpower Group acquired Dendreon, marking the first time a Chinese enterprise has ever acquired an American-made innovative biotechnology. Through this transaction, Sanpower Group has acquired not only the global intellectual property rights of the cellular immunotherapy medicine Provenge but also Dendreon’s production technology, research, and development platform and talented team. This also means that Sanpower has thus become a leading company in the cutting-edge precision medical care industry worldwide. In July 2018, the investment of Dendreon to Nanjing Cenbest was approved by the China Securities Regulatory Commission, and the asset delivery has been completed.

Dendreon China

Shanghai Dendreon Bio-Pharmaceutical Technology co., LTD. (Dendreon China), an innovative bio-pharmaceutical company, was established in early 2018 and is located in the core area of Zhangjiang Pharmaceutical Valley.

The company is committed to the research and development, production and marketing of tumor cell immunotherapy products, aiming to transfer the cutting-edge immunotherapy technology of Dendreon US to China, establish industry-leading production standards, and promote the development of the field of cellular immunotherapy in China. With Provenge's successful experience in the United States, than Dendreon China will provide high-quality products and services to Chinese patients and make it possible to develop more types of cellular immunotherapy for tumors. Relying on the strong independent research and development ability, advanced IT system and strict SOP management measures of California cell factory, IT can provide strong guarantee for the production and quality control of domestic cellular immune products.

Dendreon China's first laboratory in China was built in Zhangjiang in October 2018. The laboratory covers an area of about 2,000 square meters, among which about 1,500 square meters are clean production and testing areas. The overall design is based on the design of than Dendreon US factory in the United States, and in accordance with the requirements of GMP in China, a total of 7 workstations are set, with the designed annual capacity of 700 patients. Dendreon China is in the process of technology transfer and will provide production services for product registration and listing after completion.

Global Cord Blood Bank

As a life science enterprise dedicated to the storage of umbilical cord blood hematopoietic stem cells, Global Cord Blood Corporation (NYSE:CO) endeavours to provide umbilical cord blood hematopoietic stem cells storage services for new-borns in China and other Asian regions.

CO is the first cord blood banking operator approved by the National Health and Family Planning Commission (NHFPC), the People’s Republic of China, to engage in the cord blood hematopoietic stem cells banking business. It provides cord blood hematopoietic stem cells storage services and enjoys exclusive operation right in Beijing Municipality, Guangdong Province and Zhejiang Province, and also has a partial interest in terms of exclusively operating Shandong Cord Blood Bank. CO is also the major shareholder of Southeast Asia’s largest cord blood bank operator-Cordlife Group Limited (Cordlife, SGX:P8A.SG).

In addition, as the largest specialised cord blood stem cells banking operator in China, CO is also one of the founders of the highly recognised non-profit organisation—AsiaCORD (Asia Cord Blood Bank) Organisation.

In 2016, Sanpower Group and its subsidiary Nanjing Cenbest announced their participation in founding a foundation to buy CO. In the same year, Nanjing Cenbest bought has also acquired Shandong Cord Blood Bank in the same year., and As a result, Sanpower now holds four licences out of the only seven issued provincial-level cord blood bank licences in China. It has reserved over 1,250,000 cord blood samples at home, and the associated reserves amount to almost 1,600,000 when counting in the Cordlife reserves across quite a few Southeast Asian countries and regions. This means that Nanjing Cenbest has emerged as the world’s largest cord blood banking operator.

Cordlife

Cordlife Group Limited was established in 2001 and went public on the Singapore Exchange (SGX:P8A) in 2012. It is the biggest storage service provider for umbilical cord blood hematopoietic stem cells and umbilical cord membrane in Southeast Asia, with over 17 years of experience in operating a cord blood bank.

The company has established a private cord blood banks network in the Asia-Pacific region. At present, it operates advanced umbilical cord blood processing and cold chain storage devices in Singapore, Hong Kong China, Indonesia, India, Malaysia and Philippines, all of which are leaders in their local market. Its cord blood banks in Singapore, Hong Kong and India are certified by the American Association of Blood Banks (AABB) and meet the world’s most advanced standards for private cord blood bank. The company’s cord blood bank in Singapore has been accredited by NetCord-FACT, making it the first cord blood bank in Southeast Asia to meet those two international standards. It is one of the only seven cord blood banks in the world to meet the NetCord-FACT standard.

Cordlife also provides products and services to Malaysia and Thailand through its subsidiaries and partners. The company is the largest shareholder of Stemlife, the leading private cord blood bank in Malaysia. Meanwhile, Stemlife is the main shareholder of Thai Stemlife, the biggest private cord blood bank in Thailand.

In June 2016, Nanjing Cenbest acquired 20% of Cordlife’s equity, which promotes the further expansion of its umbilical cord blood business in Southeast Asia.

Qilu Stem Cell

Shandong Qilu Stem Cell Engineering Co., Ltd. (Qilu Stem Cell) was incorporated in 2004. Shandong Cord Blood Bank, which was jointly established by Qilu Stem Cell and Shandong University’s Qilu Hospital, is one of the seven cord blood banks approved by the National Health Commission and the only legitimate cord blood stem cells preservation organisation in Shandong Province. It is mainly engaged in the storage, clinical research and technology development of cord blood stem cells and other business. In 2016, Nanjing Cenbest, a listed company under Sanpower Group, announced its acquisition of a 76% ownership stake in Qilu Stem Cell.

Over more than ten years, Shandong Cord Blood Bank has reserved more than 300,000 tubes of cord blood stem cells and provided nearly 1,500 vials of cord blood for clinical stem cell transplantation. By making full use of specialized stem cell preparation technology and its strong capabilities in clinical application, Shandong Cord Blood Bank has produced a series of important results in clinical research on stem cells, cell-induced differentiation and amplification technology, tissue cryopreservation research and genetic testing, among other areas.

In the future, Shandong Cord Blood Bank will continue to give full play to its strengths in the medicine, science, research and production systems and to build a biological high-tech base revolving around cord blood stem cell research.

Find Bio-Tech

Shanghai Find Bio-Tech Co., Ltd. (Find Bio-Tech) is a high-tech enterprise centered on the clinical application of high throughput sequencing (HTS) and is a leading enterprise in the field of clinical transformation and application of genetic sequencing in domestic China. The company has a complete system of R&D, registration, laboratory testing and customer service, with all kinds of advanced international platforms including high throughput sequencing (HTS), mass spectra spectrometric detection and high-performance computing platforms, and has independent intellectual property rights and leading bio-information analysis technology.

Find Bio-Tech’s businesses are mainly on clinical application and popularizing testing services within the medical testing industry and it possesses the independent third-party qualification for medical testing owning medical labs in Chengdu, Shandong and so on with total area of 8,000 ㎡. The company has formed a specialized team of 400 staff and provided hundreds upon hundreds of clients with clinical services mainly on safe, accurate and quick non-invasive prenatal testing (NIPT), genetic analysis of folic acid metabolic disorder, genetic testing of monogenic inherited diseases, preimplantation genetic screening/diagnosis (PGS/PGD), chromosome abnormality testing, inherited metabolic diseases screening, etc. It also provides individualized genetic testing services including tumor targeted drugs, tumor chemotherapeutic drugs, antihypertensives, antihyperglycemics, antihyperlipidemics.